Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access phase 3b study of tarlatamab for advanced small cell lung cancer after at least two prior lines
MOH_2024-05-22_013428Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Planned start May 2024; status: not yet recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2024-05-22_013428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-22_013428.